<div id="readability-page-1"><div><p>The Central Drugs Standard Control Organisation (CDSCO) has asked states and union territories (UTs) to actively monitor print, electronic, digital, social media, and outdoor platforms for surrogate promotional activities related to weight-loss drugs such as semaglutide.</p></div><div><div><div id="article-index-0">  <p>  This comes after India’s apex drug regulatory body had asked all drugmakers having marketing authorisation to sell glucagon-like peptide (GLP-1) drugs for obesity management not to partake in any promotional activities for the prescription-only therapy.</p> </div><div id="article-index-1">  <p>  In a circular dated March 27, the CDSCO stated that appropriate action could be taken under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, against manufacturers, importers, marketers, or any other entities found in violation of the rules.</p> </div><div id="article-index-2">  <p>  “Over the past several weeks, the CDSCO, in coordination with state licensing authorities, has undertaken a nationwide enforcement drive to curb illegal distribution channels, non-compliant dispensing practices, and misuse of GLP-1 drug use,” said Drug Controller General Rajeev Raghuvanshi.</p> </div><div id="article-index-3">  <p>  He added that several audits and inspections have already been carried out, including at online pharmacy warehouses, drug wholesalers, retail outlets, and slimming clinics, with notices being served to entities found in violation of conditions of permission and on-label warnings.</p> </div><div id="article-index-4">  <p>  Recently, the Haryana Food and Drug Administration (FDA) had seized counterfeit versions of its diabetes drug Mounjaro in Gurugram.</p> </div><div id="article-index-5">  <p>  Marketed by US-based drugmaker Eli Lilly, the counterfeit products were neither manufactured by Lilly nor did they originate from the company’s authorised and verified supply chain.</p> </div><div id="article-index-6">  <p>  With Novo Nordisk’s blockbuster GLP-1 agonist drug semaglutide, better known by its brand name Ozempic, going off patent on March 20, Indian markets have been flooded with more than 25 cheaper generic versions.</p> </div><div id="article-index-7">  <p>  Consequently, several pharmaceutical companies had stepped up multimedia awareness campaigns, not directly promoting their drugs, but building awareness around obesity being a disease and encouraging users to consult doctors, as the race for India’s GLP-1 drug market intensifies.</p> </div><div id="article-index-8">  <p>  Over the past year, new launches in the injectable GLP-1 agonist segment — such as Mounjaro, Wegovy, and Ozempic — have already driven a 218 per cent rise in sales in this category on a moving annual turnover (MAT) basis to Rs 1,736 crore in April 2026, compared with Rs 545 crore in April 2025.</p> </div><div id="article-index-9">  <p>  Of these, Mounjaro and Ozempic are currently approved in India only for Type-2 diabetes, and prescriptions are restricted to diabetic patients.</p> </div><div id="article-index-10">  <p>  However, with awareness among the broader population limited, companies are turning to multimedia campaigns focused on obesity awareness since Indian regulations prohibit direct-to-consumer drug advertising.</p> </div><div id="article-index-11">  <p>  India’s large disease burden has also made it an attractive market for weight-loss therapies. According to World Health Organization (WHO) estimates for 2023-24, the country has around 101 million people living with diabetes, and another 136 million with pre-diabetes.</p> </div><div id="article-index-12">  <p>Studies suggest India also has 254 million people with generalised obesity, and 351 million with abdominal obesity.</p> </div></div></div></div>

諾和諾德公司

<p>印度中央藥品標準控制組織（CDSCO）已指示各州和聯邦直轄區監控 GLP-1 減肥藥物（如 semaglutide）的推廣活動，此舉是在對處方藥物的推廣活動實施禁令之後。該組織通過審計和檢查來強制執行合規，解決非法分銷和濫用問題。隨着 semaglutide 專利的到期，已有超過 25 種仿製藥版本問世，促使公司推出以肥胖意識為重點的多媒體宣傳活動，因為直接廣告是被禁止的</p>

印度中央藥品標準控制組織（CDSCO）要求各州和聯邦屬地監控 GLP-1 藥物的替代性促銷活動